Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment.

Autor: Corassa M; Medical Oncology Department, A.C. Camargo Cancer Center, R. Professor Antonio Prudente, São Paulo, Brazil., Abreu RF; Department of Pathology, R. Professor Antonio Prudente, São Paulo, Brazil., de Lima VCC; Medical Oncology Department, A.C. Camargo Cancer Center, R. Professor Antonio Prudente, São Paulo, Brazil., Torrezan GT; Genomics and Molecular Biology Group, International Research Center/CIPE, A.C. Camargo Cancer Center, São Paulo, Brazil.; National Institute of Science and Technology in Oncogenomics (INCITO), São Paulo, Brazil., Cavalher FP; Medical Oncology Department, A.C. Camargo Cancer Center, R. Professor Antonio Prudente, São Paulo, Brazil., Silva TN; Department of Pathology, R. Professor Antonio Prudente, São Paulo, Brazil., Oliveira TB; Medical Oncology Department, A.C. Camargo Cancer Center, R. Professor Antonio Prudente, São Paulo, Brazil., Freitas HC; Medical Oncology Department, A.C. Camargo Cancer Center, R. Professor Antonio Prudente, São Paulo, Brazil., Carraro DM; Genomics and Molecular Biology Group, International Research Center/CIPE, A.C. Camargo Cancer Center, São Paulo, Brazil.; National Institute of Science and Technology in Oncogenomics (INCITO), São Paulo, Brazil., Costa FD; Department of Pathology, R. Professor Antonio Prudente, São Paulo, Brazil.
Jazyk: angličtina
Zdroj: JCO precision oncology [JCO Precis Oncol] 2022 Oct; Vol. 6, pp. e2200367.
DOI: 10.1200/PO.22.00367
Databáze: MEDLINE